Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
Bristol-Myers Squibb
Aulos Bioscience, Inc.
ImmunityBio, Inc.
University of Pittsburgh
Mayo Clinic
University of Pittsburgh
University of Pittsburgh
7 Hills Pharma, LLC
Incyte Corporation
Toray Industries, Inc
Memorial Sloan Kettering Cancer Center
Sarcoma Oncology Research Center, LLC
University of California, San Diego
Children's National Research Institute
Eli Lilly and Company
Molecular Templates, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Biomica Ltd.
University Hospital, Ghent
Rutgers, The State University of New Jersey
HUYABIO International, LLC.
Fate Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Cambridge University Hospitals NHS Foundation Trust
Incyte Corporation
University College, London
Duke University
Genocea Biosciences, Inc.
Bristol-Myers Squibb
Sheba Medical Center
BioNTech SE
MultiVir, Inc.
Bristol-Myers Squibb